Furthermore, previous RNA-seq from our ‘poorly differentiated’ Tfh vs. ‘normal’ Tfh cells identified Il18r as a potential driver of Tfh differentiation.9 IL18 is a pro-atherogenic cytokine11 that belongs to the IL1 family, and after the successful CANTOS trial results demonstrating the benefit of targeting IL1β in coronary artery disease (CAD), IL18 has been postulated as an alternative target.12 Its pro-atherogenic role in mice so far was attributed to its effect on Th cell differentiation and IFNγ production,13 but its role in Tfh differentiation has not been studied before. This evidence concerns the gene IL18R1 and coronary artery disorder.